Outlook Therapeutics, Inc.
OTLK · XNASCIK 1649989fmd_1J9RJQW3S8SW7STQZSDCTM8YMGManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Oct 01, 2014 to Jun 30, 2026, 46 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 3 | 4 | 3 | 8 | – | – | – | – | – | 1 |
| Net interest income | – | – | – | – | (2) | (1) | (1) | (2) | (3) | (0) |
| Cost of revenue | – | – | – | – | – | – | – | – | – | 1 |
| Gross profit | – | – | – | – | – | – | – | – | – | 0 |
| Research and development | 33 | 24 | 19 | 24 | 26 | 39 | 42 | 26 | 42 | 27 |
| Selling, general and administrative | – | – | – | – | – | – | – | – | 30 | 40 |
| Total operating expenses | 54 | 40 | 33 | 44 | 37 | 52 | – | – | – | – |
| Operating income | (51) | (36) | (30) | (36) | (37) | (52) | (63) | (53) | (72) | (67) |
| Interest expense | 2 | 6 | 4 | 3 | 2 | – | – | 3 | 3 | – |
| Interest and investment income | – | – | – | – | – | – | – | 1 | 1 | 0 |
| Income before taxes | (53) | (38) | (34) | (38) | (39) | (53) | (66) | (59) | (75) | (64) |
| Income tax expense | 0 | 1 | (4) | (3) | (3) | 0 | 0 | 0 | 0 | (2) |
| Net income from continuing operations | (53) | (39) | (30) | (35) | (35) | (53) | (66) | (59) | (75) | (62) |
| Net income | (53) | (39) | (30) | (35) | (35) | (53) | (66) | (59) | (75) | (62) |
| Net income to common shareholders | (63) | (40) | (48) | (36) | (49) | (53) | (66) | (59) | (75) | (62) |